DOC's Q3 25/26 developed broadly in line with expectations. While fx-adj. growth was strong, reported results were mixed.
13 Feb 2026
Q3 review: fx distorts, margins improve
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Q3 review: fx distorts, margins improve
- Published:
13 Feb 2026 -
Author:
Simon Keller, CFA -
Pages:
12 -
DOC's Q3 25/26 developed broadly in line with expectations. While fx-adj. growth was strong, reported results were mixed.